$SURF 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.

CEO

J. Jeffrey Goater

Exchange

NASDAQ

Website

www.surfaceoncology.com

$90M

Total Revenue

51

Employees

$329M

Market Capitalization

14.71

Price/Earning ratio

Similar Companies

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Charles River Laboratories Int CRL 21115 3273 9.00 53.28 12.10
Exact Sciences Corp. EXAS 15524 1712 4.63 -17.52 -49.89
PRA Health Sciences Inc PRAH 10739 3333 6.88 50.52 6.40
Syneos Health Inc SYNH 9147 4730 2.78 38.89 4.99
Medpace Holdings Inc MEDP 7055 1028 7.81 40.02 17.02
Exelixis Inc EXEL 6902 1157 3.31 74.14 8.13
Twist Bioscience Corp TWST 5634 127 9.68 -42.81 -106.59
Allakos Inc ALLK 5438 9.89 -27.30 None
Vir Biotechnology Inc VIR 5162 183 7.14 -17.02 -162.74
Sana Biotechnology Inc SANA 3669 4.21 -11.20 None
Recursion Pharmaceuticals Inc RXRX 3242 9 5.07 -26.44 None
Lyell Immunopharma Inc LYEL 3126 8 3.06 -16.15 None
Instil Bio Inc TIL 2312 0 3.63 -28.00 None
Alx Oncology Holdings Inc ALXO 2166 1 5.39 -18.67 -401.23
Verve Therapeutics Inc VERV 2083 5.13 -21.06 None
Allogene Therapeutics Inc ALLO 2062 38 2.19 -8.60 -621.84
Erasca Inc ERAS 2055 -14.41 -16.25 None
Sorrento Therapeutics Inc SRNE 1840 51 11.05 -5.81 -626.43
Cortexyme Inc CRTX 1710 11.90 -19.39 None
Constellation Pharmaceuticals CNST 1564 4.32 -11.18 None
Castle Biosciences Inc CSTL 1554 78 4.09 -66.91 -28.88
Pandion Therapeutics Inc PAND 1501 1069 1.83 -13.34 -10.55
AlloVir Inc ALVR 1480 0 5.06 -12.56 -718.59
Replimune Group Inc REPL 1458 2.91 -16.17 None
Organogenesis Holdings Inc ORGO 1372 433 7.83 18.15 16.17
Rubius Therapeutics Inc RUBY 1330 5.45 -7.67 None
Y-Mabs Therapeutics Inc YMAB 1138 37 4.92 -24.73 -114.04
National Research Corp NRC 1129 140 14.47 31.01 25.62
Caribou Biosciences Inc CRBU 1098 5 -24.96 -21.71 -955.31
Century Therapeutics Inc IPSC 1076 2.42 -15.44 None
Monte Rosa Therapeutics Inc GLUE 1016 2.94 -17.64 None
Cullinan Oncology Inc CGEM 946 19 2.06 -17.35 -284.59
Scholar Rock Holding Corp SRRK 901 16 4.21 -8.33 -687.82
Precigen Inc PGEN 898 101 6.34 -8.13 -107.45
Janux Therapeutics Inc JANX 882 1 2.33 -76.82 -436.67
RAPT Therapeutics Inc RAPT 803 5 4.35 -13.37 7.14
Sutro Biopharma Inc STRO 792 69 2.83 -8.69 -114.69
Imago BioSciences Inc IMGO 776 -9.97 -29.79 None
Design Therapeutics Inc DSGN 765 0 1.91 -39.74 -245.44
MeiraGTx Holdings plc MGTX 723 19 3.80 -12.51 -325.95
Graphite Bio Inc GRPH 718 1.96 -14.58 None
Ideaya Biosciences Inc IDYA 709 36 3.65 -27.21 -84.49
Crinetics Pharmaceuticals Inc CRNX 693 0 3.99 -7.81 -447.78
Talaris Therapeutics Inc TALS 646 2.43 -18.98 None
Precision Biosciences Inc DTIL 556 101 5.88 -11.16 -45.88
Vor Biopharma Inc VOR 546 2.19 -8.34 None
Acumen Pharmaceuticals Inc ABOS 541 1 -5.30 -5.57 -550.91
Rallybio Corp RLYB 526 38 -7.86 -12.39 -1.07
Mirum Pharmaceuticals Inc MIRM 463 11 5.26 -3.04 None
Werewolf Therapeutics Inc HOWL 457 2.47 -2.45 None
Kezar Life Sciences Inc KZR 449 3.26 -9.36 None
Applied Therapeutics Inc APLT 430 14 3.84 -3.77 -19.41
Evelo Biosciences Inc EVLO 401 7.05 -3.79 None
Cue Biopharma Inc CUE 367 5 5.30 -8.50 -802.84
Oyster Point Pharma Inc OYST 360 2.38 -4.51 None
Vera Therapeutics Inc VERA 355 3.91 -6.48 None
Biomea Fusion Inc BMEA 340 1.68 -18.06 None
Sera Prognostics Inc SERA 335 0 -2.33 -14.21 None
Surface Oncology Inc SURF 329 90 2.35 14.71 18.99
Aerovate Therapeutics Inc AVTE 328 -16.22 -22.30 None
Magenta Therapeutics Inc MGTA 325 1.88 -4.68 None
Cabaletta Bio Inc CABA 312 3.20 -8.02 None
Luna Innovations Inc LUNA 299 101 3.70 129.57 2.46
Black Diamond Therapeutics Inc BDTX 284 1.14 -2.71 None
INmune Bio Inc INMB 256 0 7.54 -13.13 None
Pieris Pharmaceuticals Inc PIRS 253 24 6.35 -5.23 -203.73
Compass Therapeutics Inc CMPX 253 8.68 -3.11 None
Candel Therapeutics Inc CADL 247 0 -6.58 -7.10 None
Nextcure Inc NXTC 241 22 0.90 -3.56 -163.57
Sensei Biotherapeutics Inc SNSE 218 1.32 -7.63 None
AquaBounty Technologies Inc AQB 216 0 1.23 -10.59 None
Gemini Therapeutics Inc GMTX 211 1088 0.23 1.74 11.24
Alzamend Neuro Inc ALZN 197 12.61 -32.43 None
Impel NeuroPharma Inc. IMPL 182 3.65 -3.76 None
Elevation Oncology Inc ELEV 179 1.16 -8.02 None
Tscan Therapeutics Inc TCRX 174 6 -2.90 -5.07 -563.14
Hookipa Pharma Inc HOOK 152 20 1.20 -2.48 -304.07
Reneo Pharmaceuticals Inc RPHM 151 0.92 -5.54 None
Unity Biotechnology Inc UBX 124 1 1.93 -1.53 None
IN8bio Inc INAB 112 -5.24 -11.17 None
HCW Biologics Inc HCWB 109 4 -4.95 -16.95 -162.03
Exicure Inc XCUR 104 4 2.81 -2.19 -148.49
Axcella Health Inc AXLA 103 2700 2.21 -1.84 -10.84
Cyclerion Therapeutics Inc CYCN 90 4 1.76 -1.34 None
BioVie Inc BIVI 72 29.90 -0.40 None
Scopus Biopharma Inc SCPS 70 234 -35.55 -3.34 80.93
Eloxx Pharmaceuticals Inc ELOX 70 0 3.17 -1.28 -14.14
Synaptogenix Inc SNPX 65 2.05 -4.31 None
Monopar Therapeutics Inc MNPR 60 2.68 -7.56 None
NanoViricides Inc NNVC 54 1.88 -6.05 None
CohBar Inc CWBR 53 4.84 -3.17 None
Rezolute Inc RZLT 53 3.91 -2.43 None
Acurx Pharmaceuticals Inc ACXP 48 3.14 -6.00 None
Vaccinex Inc VCNX 47 1 3.53 -1.66 -48.71
Cyclo Therapeutics Inc CYTH 39 1 3.77 -1.86 -989.80
TransCode Therapeutics Inc RNAZ 38 -8.08 -10.86 None
Unicycive Therapeutics Inc UNCY 36 113 -8.79 -9.81 7.94
AgeX Therapeutics Inc AGE 35 2 -4.18 -3.68 -522.77
Aridis Pharmaceuticals Inc ARDS 35 0 -3.79 -1.40 -851.00
Cytocom Inc CBLI 30 0 3.88 -12.72 -912.16
Tenax Therapeutics Inc TENX 18 0 27.83 -0.71 -840.64
Geovax Labs Inc GOVX 16 1 1.30 -11.11 -558.09
Kiromic BioPharma Inc KRBP 15 6.91 -1.10 None
Xenetic Biosciences Inc XBIO 14 1 1.73 -1.07 -47.40
Neurotrope Inc NTRP 5 29 0.08 0.76 23.48

Is Surface Oncology Inc.’s (NASDAQ: SURF) 1.83% Gain This Week Telling Us Something New?

4d ago, source: marketingsentinel

During the last session, Surface Oncology Inc. (NASDAQ:SURF)’s traded shares were 1.21 million, with the beta value of the company hitting 1.65. At the end of the trading day, the stock’s price was $7 ...

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

7d ago, source: Yahoo Finance

Importantly, Surface Oncology, Inc. (NASDAQ:SURF) does carry debt. But the real question is whether this debt is making the company risky. Debt and other liabilities become risky for a business ...

Surface Oncology Inc. (SURF) can’t be written off after posting last 3-months Average volume of 957.00K

18d ago, source: investchronicle

Surface Oncology Inc. (SURF) is priced at $7.95 after the most recent trading session. At the very opening of the session, the stock price was $7.50 and reached a high price of $7.73, prior to closing ...

Surface Oncology Inc. (NASDAQ: SURF) Stock Forecast: Could Pass $18.00 In A Year

8d ago, source: stocksregister

The trading price of Surface Oncology Inc. (NASDAQ:SURF) floating higher at last check on Tuesday, October 12, closing at $7.98, 1.92% higher than its previous close. >> 7 Top Picks for the Post-Pande ...

Hedge Funds Aren’t Crazy About Surface Oncology, Inc. (SURF) Anymore

13d ago, source: Yahoo Finance

The following article will discuss the smart money sentiment towards Surface Oncology, Inc. (NASDAQ:SURF). Is Surface Oncology, Inc. (NASDAQ:SURF) a buy, sell, or hold? Money managers were getting ...

What Is The Ownership Structure Like For Surface Oncology, Inc. (NASDAQ:SURF)?

29d ago, source: Nasdaq

Every investor in Surface Oncology, Inc. (NASDAQ:SURF) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see ...

Investors Who Bought Surface Oncology (NASDAQ:SURF) Shares A Year Ago Are Now Down 79%

4d ago, source: Yahoo Finance

But it's not unreasonable to try to avoid truly shocking capital losses. We wouldn't blame Surface Oncology, Inc. (NASDAQ:SURF) shareholders if they were still in shock after the stock dropped like a ...

What Type Of Shareholders Own The Most Number of Surface Oncology, Inc. (NASDAQ:SURF) Shares?

4d ago, source: Yahoo Finance

Every investor in Surface Oncology, Inc. (NASDAQ:SURF) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies ...

Surface Oncology Inc.

6d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hedge Funds Aren’t Crazy About Surface Oncology, Inc. (SURF) Anymore

15d ago, source: Insider Monkey

The following article will discuss the smart money sentiment towards Surface Oncology, Inc. (NASDAQ:SURF). In the financial world there are a large number of tools investors have at their disposal ...

Surface Oncology Inc SURF

6d ago, source: Morningstar%2c Inc.

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...

Surface Oncology Inc QSOA

5d ago, source: Morningstar%2c Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Your Portfolio